explore -WSS

explore

author：focus 2025-10-01 12:33:59 - browse：5

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Steward Health Care expansion into Malta flopped

hotspot

focus

WSS

Yancopoulos of Regeneron works to expand Dupixent success

Yancopoulos of Regeneron works to expand Dupixent success

The painfully weak evidence on taking collagen to treat arthritis

With Wegovy coverage, Medicare patients may face high costs

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

CRISPR technology availability, affordability needs to be expanded

knowledge

explore

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Malaria cases in Florida and Texas: Here’s what you need to know

FTX founder Sam Bankman

How one medical school became remarkably diverse

FTX founder Sam Bankman

Medicare proposal to cover medical devices draws a mixed reaction

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Drug repurposing or repositioning? The language matters

FTX founder Sam Bankman

hotspot

CDC launches VaccineFinder tool to locate Covid

Medical devices makers are asking for forgiveness, not permission

Adam's Take: Intra

Travel bans should be based on evidence, not politics or fear

Pregnancy ages women, but effects reverse after delivery

Biden praises World Series champion Astros for impact off the field during White House celebration

hotspot

hotspot

focus

knowledge